Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Corey Casper has a total of 433 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study

    by Philip A Powell, Anju Keetharuth, Sé Maria Frances, Jill Carlton, Kelly Makarounas-Kirchmann, Antonio Adolfo Guerra Soares Brandão, Karthik Ramasamy, Francis Shupo, Kelley C Dacus, Corey Casper, et al.

    Background: Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder that is associated with a broad range of symptoms, including constitutional, gastrointestinal, neuropsychiatric, dermatologic, respiratory, and hematologic or lymphoreticular problems. These broad symptoms can impact the daily lives of people living with iMCD, creating a high symptom burden. Despite this, no robust, disease-specific patient-reported outcome measure (PROM) for subjective iMCD symptom burden exists. This limits accurate symptom monitoring, impacts sensitive end point selection in clinical trials, and represents a regulatory gap in patient-centered evidence generation when evaluating iMCD treatments. Objective: This protocol describes the international multistakeholder Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS) project. The primary aim of this project is to develop and preliminarily evaluate the measurement properties of a novel PROM for capturing symptom burden (ie, perceived symptom frequency and impact on daily life) in people living with iMCD. The central objective is to produce a valid and robust PROM that can be used to assess iMCD symptom burden in research, clinical trials, and symptom monitoring in clinical practice. Methods: The project has a mixed methods design, split into 4 sequential stages, with collaborative advisory input throughout. Stage 1 uses existing data and consultation with expert clinical and patient advisors to generate draft PROM content. Stage 2 uses qualitative cognitive debriefing interviews (n=10) to evaluate the content validity of the draft PROM content and enable meaningful revisions. Stage 3 involves a cross-sectional quantitative survey design in people living with iMCD (n≥50), allowing for psychometric analyses of structural validity (using classical test theory and/or Rasch methodology), construct validity (known-group validity and correlational methods), and internal consistency reliability (Cronbach α). Stage 4 uses a mixed methods design, including longitudinal quantitative survey evidence (n≥20) and qualitative interviews (n=10), triangulated to estimate preliminary meaningful change estimates for the new PROM. The project is international in scope, with primary data collection in 6 countries (ie, Australia, Brazil, Canada, New Zealand, the United Kingdom, and the United States). Results: Funding for ISBUS began in June 2023 and is ongoing. As of March 2026, stage 3 had been completed, with 51 people living with iMCD completing the survey, and stage 4 was ongoing, with 32 follow-up surveys completed. Analyses for stages 1-3 were completed and are expected to be published in 2026, followed by stage 4 findings in 2027. Conclusions: The aim of the ISBUS project is to produce a novel symptom burden PROM codeveloped with patients with iMCD to measure what matters to patients with iMCD. It is anticipated that the new PROM will be used in iMCD research, as a secondary end point in trials, and as a clinical tool to monitor symptom burden in the management of iMCD. Trial Registration: ClinicalTrials.gov NCT05995834; https://clinicaltrials.gov/study/NCT05995834 International Registered Report Identifier (IRRID): DERR1-10.2196/96022

  • Open Access

    Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study (Preprint)

    by Philip A Powell, Anju Keetharuth, Sé Maria Frances, Jill Carlton, Kelly Makarounas-Kirchmann, Antonio Adolfo Guerra Soares Brandão, Karthik Ramasamy, Francis Shupo, Kelley C Dacus, Corey Casper, et al.

    BACKGROUND Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder that is associated with a broad range of symptoms, including constitutional, gastrointestinal, neuropsychiatric, dermatologic, respiratory, and hematologic or lymphoreticular problems. These broad symptoms can impact the daily lives of people living with iMCD, creating a high symptom burden. Despite this, no robust, disease-specific patient-reported outcome measure (PROM) for subjective iMCD symptom burden exists. This limits accurate symptom monitoring, impacts sensitive end point selection in clinical trials, and represents a regulatory gap in patient-centered evidence generation when evaluating iMCD treatments. OBJECTIVE This protocol describes the international multistakeholder Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS) project. The primary aim of this project is to develop and preliminarily evaluate the measurement properties of a novel PROM for capturing symptom burden (ie, perceived symptom frequency and impact on daily life) in people living with iMCD. The central objective is to produce a valid and robust PROM that can be used to assess iMCD symptom burden in research, clinical trials, and symptom monitoring in clinical practice. METHODS The project has a mixed methods design, split into 4 sequential stages, with collaborative advisory input throughout. Stage 1 uses existing data and consultation with expert clinical and patient advisors to generate draft PROM content. Stage 2 uses qualitative cognitive debriefing interviews (n=10) to evaluate the content validity of the draft PROM content and enable meaningful revisions. Stage 3 involves a cross-sectional quantitative survey design in people living with iMCD (n≥50), allowing for psychometric analyses of structural validity (using classical test theory and/or Rasch methodology), construct validity (known-group validity and correlational methods), and internal consistency reliability (Cronbach α). Stage 4 uses a mixed methods design, including longitudinal quantitative survey evidence (n≥20) and qualitative interviews (n=10), triangulated to estimate preliminary meaningful change estimates for the new PROM. The project is international in scope, with primary data collection in 6 countries (ie, Australia, Brazil, Canada, New Zealand, the United Kingdom, and the United States). RESULTS Funding for ISBUS began in June 2023 and is ongoing. As of March 2026, stage 3 had been completed, with 51 people living with iMCD completing the survey, and stage 4 was ongoing, with 32 follow-up surveys completed. Analyses for stages 1-3 were completed and are expected to be published in 2026, followed by stage 4 findings in 2027. CONCLUSIONS The aim of the ISBUS project is to produce a novel symptom burden PROM codeveloped with patients with iMCD to measure what matters to patients with iMCD. It is anticipated that the new PROM will be used in iMCD research, as a secondary end point in trials, and as a clinical tool to monitor symptom burden in the management of iMCD. CLINICALTRIAL ClinicalTrials.gov NCT05995834; https://clinicaltrials.gov/study/NCT05995834 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/96022

  • Open Access

    Supplementary Figures from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

    by Nicole Thomas, Carlos A. García-Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett, Jeffrey Bethony, Jay Bowen, Anthony C. Bryan, Corey Casper, et al.

    Supplemental Figure 1. Association between genetic alterations and methylation patterns Supplemental Figure 2. Epitypes characteristics and their relation to other lymphomas. Supplemental Figure 3. Comparison of epitype characteristics in relation to EBV status. Supplemental Figure 4. Validation of epitypes using Nanopore sequencing data. Supplemental Figure 5. Selected characteristics of BL epitypes and relative aSHM frequencies in EBV-positive BL. Supplemental Figure 6. GSEA plots for SignatureDB pathways determined to be significantly different between BL epitypes. Supplemental Figure 7. The Cox proportional hazards models accounting for both BL epitype and TP53 mutation status in adult BLs.

  • Open Access

    Supplementary Tables from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

    by Nicole Thomas, Carlos A. García-Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett, Jeffrey Bethony, Jay Bowen, Anthony C. Bryan, Corey Casper, et al.

    S1. DMRs EBVpos vs CB S2. DMRs EBVneg vs CB S3. Shared DMRs EBV S4. DMRs EBV status S5. Methylation gene corrs EB S6. GO pathways enrichment S7. LPS selected probes S8. Epitype assignment S9. DMRs eptiype S10. DMR gene corrs epitype S11. JASPAR TF results epitype S12. JASPAR TF results EBV S13. aSHM epitype S14. DEG epitpye S15. SignatureDB pathways enrichment

  • Open Access

    DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

    by Nicole Thomas, Carlos A. García-Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett, Jeffrey Bethony, Jay Bowen, Anthony C. Bryan, Corey Casper, et al.

    The genetic subtypes of Burkitt lymphoma have been defined, but the role of epigenetics remains to be comprehensively characterized. We searched genomic DNA from 218 patients across four continents for recurrent DNA methylation patterns and their associations with clinical and molecular features. We identified DNA methylation patterns that were not fully explained by the Epstein–Barr virus status or mutation status, leading to two epitypes described here as HypoBL and HyperBL. Each is characterized by distinct genomic and clinical features including global methylation, mutation burden, aberrant somatic hypermutation, and survival outcomes. Methylation, gene expression, and mutational differences between the epitypes support a model in which each arises from a distinct cell of origin. These results, pending validation in external cohorts, point to a refined risk assessment for patients with Burkitt lymphoma who may experience inferior outcomes. Significance: Burkitt lymphoma can be divided into two epigenetic subtypes (epitypes), each carrying distinct biological, transcriptomic, genomic, and clinical features. Epitype is more strongly associated with clinical and mutational features than the Epstein–Barr virus status or genetic subtype, highlighting an important additional layer of Burkitt lymphoma pathogenesis.


  • Open Access

    Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry

    by Sheila K. Pierson, Joshua D. Brandstadter, Drew A. Torigian, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Corey Casper, Amy Chadburn, Shanmuganathan Chandrakasan, Angela Dispenzieri, et al.

    Castleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the 2 forms of CD with unknown etiology, unicentric CD (UCD), and human herpesvirus-8–negative/idiopathic multicentric CD (iMCD). Whereas UCD cases typically present with localized lymphadenopathy and mild symptoms, iMCD involves multicentric lymphadenopathy and cytokine storm–driven symptoms with 3 recognized clinical phenotypes. Increasingly, there are anecdotal reports of cases that do not fit into this framework, but these cases have not been systematically described. Herein, we use the ACCELERATE natural history registry to characterize the spectrum of CD based on disease features, symptomatology, and severity. Our results characterize a cohort of 179 CD cases, which were reviewed and confirmed by an expert panel of clinicians and hematopathologists. We show that patients with CD present on a continuous spectrum of clinical phenotypes, and we describe oligocentric CD (OligoCD), an intermediate phenotype that does not fit the criteria for UCD or iMCD. These cases tend to have “oligocentric” lymphadenopathy (median [interquartile range] regions of lymphadenopathy, 3.0 [2.0-4.0]) in a regional pattern and exhibit a mild clinical phenotype that is more similar to UCD than iMCD. We also show that patients with OligoCD are inconsistently categorized as UCD vs iMCD, highlighting the need for this characterization. Future data collected through ACCELERATE may further elucidate the natural history and risk profile of these patients.


  • Open Access

    Development of an Intranasally- and Intramuscularly-Administrable Replicon Vaccine Efficacious Against H5N1 Influenza Virus

    by Wynton D. McClary, Devin S. Brandt, Madeleine F. Jennewein, Jasneet Singh, Samuel Beaver, Matthew R. Ykema, Christopher Press, Eduard Melief, Julie Bakken, Pauline Fusco, et al.

    The risk of a respiratory viral pandemic is significant, including from the now widespread panzootic H5N1 influenza virus, highlighting the need for effective, stable, and inexpensive vaccine technologies that elicit strongly protective immunity. Intranasal vaccines can stimulate local immune responses at the site of natural respiratory viral infection, a key characteristic that can not only reduce morbidity and mortality caused by respiratory viruses but also potentially reduce viral transmissibility to limit outbreaks. Nucleic acid vaccines are now a valuable tool in pandemic responses, with high potency and rapid adaptability to target circulating or emerging viral strains; however, data are limited on which vaccine attributes are needed for efficient transmucosal delivery and immune stimulation following intranasal delivery. To demonstrate proof of concept, here we have developed a replicon vaccine expressing an H5 influenza antigen that uses a nanostructured lipid carrier (NLC) delivery system. A relationship was established between the molar ratio of positive charges on the NLC to the negative charges on the nucleic acid (N:P ratio) and the immunogenicity of the vaccine formulations, with higher N:P ratios resulting in an increase in vaccine immunogenicity. We demonstrated the ability of this replicon vaccine to be administered via intramuscular and intranasal routes with a singular vaccine formulation. The vaccine induced systemic immunity when dosed intramuscularly or intranasally in an immunocompetent mouse model, whereas intranasal dosing uniquely stimulated a strong mucosal immune response. Moreover, a mixed intramuscular/intranasal dosing strategy using this unified formulation stimulated a balanced systemic and mucosal immune response. Finally, we demonstrated the protective efficacy of this intranasally and intramuscularly/intranasally delivered H5 replicon-NLC vaccine against morbidity and mortality in a lethal H5N1 influenza challenge ferret model. This work establishes the replicon-NLC vaccine platform as a potential novel intranasal technology for rapid pandemic response.


  • Open Access

    An intranasal, NLC-delivered self-amplifying RNA vaccine establishes protective immunity against pre-pandemic H5N1 and H7N9 influenza

    by Matthew R. Ykema, Michael A. Davis, Darshan N. Kasal, Madeleine F. Jennewein, Ethan Lo, Jasneet Singh, Samuel Beaver, Noah Cross, Eduard Melief, Sierra Reed, et al.

    Seasonal and pandemic influenzas are continuous threats to human health, requiring rapid development of vaccines to multiple evolving viral strains. New RNA vaccine technologies have the adaptability and manufacturability to facilitate pandemic preparedness but have limited flexibility in their route of administration, reducing the ability to establish local protective immune responses such as respiratory mucosal immunity. Here, we describe monovalent and bivalent self-amplifying RNA (saRNA) vaccines against A/Vietnam/1203/2004 H5N1 and A/Anhui/2013 H7N9. These saRNA vaccines express either H5 or H7 hemagglutinin and are formulated with a nanostructured lipid carrier (NLC) that permits both intramuscular (IM) and intranasal (IN) dosing. In mice, IM vaccination established systemic humoral and cellular responses but no detectable mucosal response, while IN administration induced robust systemic and mucosal immunity. The saRNA-NLC vaccines provided complete protection against morbidity and mortality in ferret challenge models, establishing this intranasally-administered saRNA-NLC vaccine platform as a potential pandemic response tool. ONE SENTENCE SUMMARY: A self-amplifying RNA-NLC vaccine, delivered intranasally, induces robust mucosal immunity in mice and protects against H5N1 and H7N9 in ferrets


  • Open Access

    Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques

    by Mayuresh M. Abhyankar, Feifan Xu, Deborah Chavez, Anna Goodroe, Elda Mendoza, Christopher Chen, Dhiraj K. Singh, Fernando Varnador, Sandra J. Sivananthan, Robert Kinsey, et al.

    Entamoeba histolytica, the causative agent of amebiasis, is one of the top three parasitic causes of mortality worldwide. However, no vaccine exists against amebiasis. Using a lead candidate vaccine containing the LecA fragment of Gal-lectin and GLA-3M-052 liposome adjuvant, we immunized rhesus macaques via intranasal or intramuscular routes. The vaccine elicited high-avidity functional humoral responses as seen by the inhibition of amebic attachment to mammalian target cells by plasma and stool antibodies. Importantly, antigen-specific IFN-γ-secreting peripheral blood mononuclear cells (PBMCs) and IgG/IgA memory B cells (BMEM) were detected in immunized animals. Furthermore, antigen-specific antibody and cellular responses were maintained for at least 8 months after the final immunization as observed by robust LecA-specific BMEM as well as IFN-γ+ PBMC responses. Overall, both intranasal and intramuscular immunizations elicited a durable and functional response in systemic and mucosal compartments, which supports advancing the LecA+GLA-3M-052 liposome vaccine candidate to clinical testing.


  • Open Access

    Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination

    by Saishravan Shyamsundar, Sheila K. Pierson, Caoilfhionn M. Connolly, Mayan Teles, Dorry L. Segev, William A. Werbel, Frits van Rhee, Corey Casper, Joshua D. Brandstadter, Ariela Noy, et al.